Gefitynib in first line treatment of patient with adenocarcinoma of the lung with EGFR exon 18 mutation

Abstract

Non-small-cell lung cancer is one of the major health issues in Poland. EGRF tyrosine kinase inhibitors may be used to treat patients with advanced adenocarcinoma of the lung and remaining in good performance status, with appropriate renal and liver function, without severe comorbidities, and with mutations in the EGRF gene. Until now, the treatment with gefinitib has been applied for the patients with mutations in exon 19 and 21 of the EGRF gene. Efficacy of TKI in the case of the patients with rare activating mutation in exon 18 is not well investigated. This report describes the treatment of 67-year old woman with diagnosed NSCLC with activating mutation in exon 18 who received gefinitib which resulted in 13 months progression-free survival. The treatment was well-tolerated by the patient.